FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.
Bock is a recognized life science leader who built four entrepreneurial organizations that created major impact for both patients and investors, achieving leadership in their fields. He successfully spearheaded new medical paradigms and fast-growing markets such as cancer precision medicine, ultra-rare disorders and cancer prevention.
“We are delighted to welcome Thomas Bock to Notable’s board of directors,” said Laurie Heilmann, Notable CEO. “Thomas’ wealth of experience leading worldwide medical affairs divisions at top tier pharma organizations such as Novartis, Celgene and Alexion will be of great value to Notable. Thomas developed and commercialized six lifesaving, paradigm-changing blockbuster medicines in cancer, ultra-rare disorders and inflammation. Thomas brings tremendous industry knowledge and experience, which will be instrumental in navigating and supporting Notable’s path forward to becoming a world class leader in drug selection and patient treatment of hematological cancers.”
“I’m excited to join the board at Notable, a company well-positioned to fundamentally influence drug selection throughout clinical research and treatment,” said Bock. “I have spent my career as a champion of bold, industry-redefining innovations, technologies and drugs — all in the name of patient-centric treatment advances. I look forward to helping Notable maximize its impact in this arena, better serving those most in need.”